GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to
release its second quarter 2011 earnings results before market open on
Friday, August 5, 2011. Management will hold a conference call to review
the Company's second quarter 2011 performance starting at 9:00 a.m.
(Eastern Time) on the same day. The conference call will be concurrently
webcast. The link to the webcast will be available on the GenMark
Diagnostics, Inc. website at www.genmarkdx.com
under the investor relations section and will be archived for future
reference.
To listen to the conference call, please dial (877) 312-5847 (US/Canada)
or (253) 237-1154 (International) and use the conference ID number
"83859663" approximately five minutes prior to the start time.
About GenMark Diagnostics
GenMark Diagnostics is a leading provider of automated, multiplex
molecular diagnostic testing systems that detect and measure DNA and RNA
targets to diagnose disease and optimize patient treatment. GenMark's
eSensor® XT-8 system supports a broad range of molecular diagnostic
tests with a compact, easy-to-use workstation and self-contained,
disposable test cartridges. GenMark tests that are FDA cleared for IVD
use include the Cystic Fibrosis Genotyping Test, Warfarin Sensitivity
Test, and Thrombophilia Risk Test. A Respiratory Viral Panel (RVP) is
currently undergoing a clinical trial and tests for HCV Genotyping,
2C19, and KRAS are in development. For more information, visit www.genmarkdx.com.
